Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$26.24 - $39.63 $50.1 Million - $75.7 Million
1,910,414 Added 149.03%
3,192,342 $126 Million
Q1 2023

May 15, 2023

SELL
$18.67 - $24.56 $21.4 Million - $28.2 Million
-1,148,521 Reduced 47.26%
1,281,928 $31.2 Million
Q4 2022

Feb 13, 2023

BUY
$17.24 - $23.95 $234,084 - $325,193
13,578 Added 0.56%
2,430,449 $52 Million
Q3 2022

Nov 14, 2022

SELL
$9.4 - $18.59 $41,839 - $82,744
-4,451 Reduced 0.18%
2,416,871 $43.4 Million
Q2 2022

Aug 11, 2022

BUY
$9.12 - $18.9 $21.1 Million - $43.8 Million
2,317,598 Added 2234.39%
2,421,322 $23.3 Million
Q1 2022

May 13, 2022

BUY
$12.15 - $16.83 $394,656 - $546,672
32,482 Added 45.59%
103,724 $1.75 Million
Q4 2021

Feb 11, 2022

SELL
$13.83 - $18.78 $6.58 Million - $8.94 Million
-475,961 Reduced 86.98%
71,242 $1.19 Million
Q3 2021

Nov 04, 2021

BUY
$7.07 - $17.5 $696,684 - $1.72 Million
98,541 Added 21.96%
547,203 $8.89 Million
Q2 2021

Aug 11, 2021

BUY
$5.69 - $7.17 $13,121 - $16,534
2,306 Added 0.52%
448,662 $2.83 Million
Q1 2021

May 13, 2021

SELL
$5.08 - $6.89 $1.02 Million - $1.39 Million
-201,742 Reduced 31.13%
446,356 $2.76 Million
Q4 2020

Feb 16, 2021

BUY
$5.65 - $7.66 $3.16 Million - $4.28 Million
558,853 Added 626.2%
648,098 $4.48 Million
Q3 2020

Nov 12, 2020

BUY
$4.01 - $6.29 $274,612 - $430,751
68,482 Added 329.83%
89,245 $503,000
Q2 2020

Aug 13, 2020

SELL
$3.06 - $6.6 $2.45 Million - $5.29 Million
-801,287 Reduced 97.47%
20,763 $106,000
Q1 2020

May 14, 2020

BUY
$2.83 - $8.44 $2.33 Million - $6.94 Million
822,050 New
822,050 $2.83 Million
Q4 2019

Feb 14, 2020

SELL
$0.93 - $8.58 $8,595 - $79,304
-9,243 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$1.09 - $1.29 $142,906 - $169,128
-131,107 Reduced 93.41%
9,243 $10,000
Q2 2019

Aug 14, 2019

BUY
$1.21 - $1.48 $169,823 - $207,718
140,350 New
140,350 $182,000

Others Institutions Holding ISEE

About IVERIC bio, Inc.


  • Ticker ISEE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,078,000
  • Description
  • IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...
More about ISEE
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.